Gene Therapy Trials In EU Delayed By Environmental Considerations
Executive Summary
Pharmaceutical companies in the EU are becoming keener to experiment with genetically-modified advanced therapy medicinal products in patients, but they are finding it hard to navigate through the maze of environmental risk assessment procedures in each member state.
You may also be interested in...
Commission Offers Fixes To Speed Up EU Trials Of GMO-Containing ATMPs
The European Commission is making use of opportunities available under existing legislation to help facilitate clinical trials of advanced therapy products containing genetically modified organisms.
EU Sets Up Database Of National GMO Requirements To Facilitate ATMP Trials
The European Commission has developed a database to help drug companies navigate the complex process of seeking environmental clearance from EU member states before they can initiate a clinical trial with ATMPs containing a genetically modified organism.
EMA Identifies Steps To Foster ATMP Development
EU biotech companies have welcomed the various initiatives that the European Medicines Agency has listed to support the development of advanced therapy medicinal products. However, they want clear timelines on completing these initiatives since their implementation will not require any changes to the current legislative framework.